Attachment B - Specifications - Pages 1-2.docx
DOCX document 16 KB Posted
- Attached to
- Molecular Diagnostics Analyzer - LDH-OPH Bid Cancelled: 05/22/2025 - Addendum No. 1 – CANCELLATION Date Issued: 05/22/2025 Your reference State and local contract opportunity
- Solicitation number
- 3000024682
- Issued by
- East Baton Rouge Parish, Baton Rouge City, Louisiana
About this file
This document is Attachment B - Specifications for a Molecular Diagnostic Analyzer procurement by the Louisiana Department of Health - Office of Public Health (LDH-OPH), solicitation number 3000024682. The contract seeks a molecular diagnostic analyzer capable of performing multiplex tests for COVID-19, Influenza A, Influenza B, and potentially RSV, with an estimated annual testing volume of 1,250 tests. The initial contract term is 12 months beginning July 1, 2025, with potential two 12-month renewals, totaling a maximum 36-month contract duration. The system must provide first results within 115 minutes, support nasal and nasopharyngeal swab samples, and be FDA approved or emergency use authorized.
The procurement will be awarded on an all-or-none basis to the lowest responsive and responsible bidder, with preference given to Louisiana-based businesses. The contract is funded through next fiscal year appropriations and is contingent on legislative funding, meaning delivery cannot occur prior to July 1, 2025. All products must be new, current models, and include the manufacturer's standard warranty. Pricing must be inclusive of freight charges and remain firm for the entire contract period. The system must have advanced features such as a built-in barcode scanner, touchscreen computer, printer, and capabilities to detect various virus strains, including emerging COVID-19 variants, with design elements focused on minimizing human error.
View the file
Other files for this state and local contract opportunity
| File | Type | Posted |
|---|---|---|
| Attachment A - Special Terms and Conditions - Pages 1-7.pdf | ||
| 3000024682-1.pdf | ||
| Attachment C - Online Bidding Instructions - Pages 1-10.pdf | ||
| 3000024682.pdf | ||
| Attachment B - Specifications - Pages 1-2.docx | DOCX document | |
| Attachment A - Special Terms and Conditions - Pages 1-7.pdf | ||
| Attachment C - Online Bidding Instructions - Pages 1-10.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Attachment B – Specifications
RFx No.: 3000024682 Title: Molecular Diagnostic Analyzer – LDH-OPH
I. Molecular Based Medical Testing Equipment A. Shall have reagent bottles designed to help minimize human error when loading.
B. Shall not require off-board reagent reconstitution.
C. Shall have operator and QC lockout.
D. Shall have a built-in barcode scanner, built-in or included computer with touchscreen and a printer.
E. Shall have the ability to change waste while processing.
F. Shall not require daily maintenance.
G. Shall accommodate multiple tube types, widths, and heights all in the same sample rack.
H. Shall have documentation detailing cross contamination checks and aerosol safety within the processing room.
II. Testing Supplies A. General
1. Pricing shall include Multiplex Test Kits for COVID-19, FLU-A, FLU-B, and, if included RSV
2. Assay shall have an internal (specimen quality) QC and external (assay quality) QC
3. Shall be able to provide first results in 115 minutes or less
4. Shall be FDA approved or emergency use authorized for diagnostic result reporting
5. Shall be able to detect Influenza A, including avian and swine variants
6. Shall be able to detect SARS-CoV-2, including emerging variants
7. Shall be able to differentiate FLU-A, FLU-B, RSV (if applicable), and SARS-CoV-2 and potential co-infections
8. Shall not require removing swab and cap from tube for testing such as utilizing pierceable caps
9. Shall have SARS-CoV sensitivity and specificity comparable to current in house methods, Thermo TaqPath with Kingfisher extraction and Hologic SARS-CoV-2 on Panther.
10. Shall have Influenza A and Influenza B sensitivity and specificity comparable to current in house methods, BioFire RP 2.1 and CDC Influenza A/B Screen.
B. Types
1. Sample type shall include nasal swab and nasopharyngeal swab
2. Transport shall be in VTM and UTM but can include others C. Quantities
1. Testing supplies to be utilized per annum are as follows: Covid-19/FluA/FluB/RSV: 1250
2. Please note that the tests indicated above shall be the estimated number of tests that shall be reserved and made available to LDH OPH Lab on an as needed basis.
File details come from the government source that posted it. Updated .